BACKGROUND: Glutathione-S-transferase (Gst) genes are downregulated in human prostate cancer, and GSTP1 silencing is mediated by promoter DNA hypermethylation in this malignancy. We examined Gst gene expression and Gst promoter DNA methylation in normal murine prostates and Transgenic Adenocarcinoma of Mouse Prostate (TRAMP) tumors. METHODS: Primary and metastatic tumors were obtained from TRAMP mice, and normal prostates were obtained from strain-matched WT mice (n = 15/group). Quantitative real-time RT-PCR was used to measure GstA4, GstK1, GstM1, GstO1, and GstP1 mRNA expression, and Western blotting and immunohistochemical staining was used to measure GstM1 and GstP1 protein expression. MassARRAY Quantitative Methylation Analysis was used to measure DNA methylation of the 5' CpG islands of GstA4, GstK1, GstM1, GstO1, and GstP1. TRAMP-C2 cells were treated with the epigenetic remodeling drugs decitabine and trichostatin A (TSA) alone and in combination, and Gst gene expression was measured. RESULTS: Of the genes analyzed, GstM1 and GstP1 were expressed at highest levels in normal prostate. All five Gst genes showed greatly reduced expression in primary tumors compared to normal prostate, but not in tumor metastases. Gst promoter methylation was unchanged in TRAMP tumors compared to normal prostate. Combined decitabine + TSA treatment significantly enhanced the expression of 4/5 Gst genes in TRAMP-C2 cells. CONCLUSIONS: Gst genes are extensively downregulated in primary but not metastatic TRAMP tumors. Promoter DNA hypermethylation does not appear to drive Gst gene repression in TRAMP primary tumors; however, pharmacological studies using TRAMP cells suggest the involvement of epigenetic mechanisms in Gst gene repression.
BACKGROUND:Glutathione-S-transferase (Gst) genes are downregulated in human prostate cancer, and GSTP1 silencing is mediated by promoter DNA hypermethylation in this malignancy. We examined Gst gene expression and Gst promoter DNA methylation in normal murine prostates and Transgenic Adenocarcinoma of Mouse Prostate (TRAMP) tumors. METHODS: Primary and metastatic tumors were obtained from TRAMPmice, and normal prostates were obtained from strain-matched WT mice (n = 15/group). Quantitative real-time RT-PCR was used to measure GstA4, GstK1, GstM1, GstO1, and GstP1 mRNA expression, and Western blotting and immunohistochemical staining was used to measure GstM1 and GstP1 protein expression. MassARRAY Quantitative Methylation Analysis was used to measure DNA methylation of the 5' CpG islands of GstA4, GstK1, GstM1, GstO1, and GstP1. TRAMP-C2 cells were treated with the epigenetic remodeling drugs decitabine and trichostatin A (TSA) alone and in combination, and Gst gene expression was measured. RESULTS: Of the genes analyzed, GstM1 and GstP1 were expressed at highest levels in normal prostate. All five Gst genes showed greatly reduced expression in primary tumors compared to normal prostate, but not in tumor metastases. Gst promoter methylation was unchanged in TRAMPtumors compared to normal prostate. Combined decitabine + TSA treatment significantly enhanced the expression of 4/5 Gst genes in TRAMP-C2 cells. CONCLUSIONS:Gst genes are extensively downregulated in primary but not metastatic TRAMPtumors. Promoter DNA hypermethylation does not appear to drive Gst gene repression in TRAMPprimary tumors; however, pharmacological studies using TRAMP cells suggest the involvement of epigenetic mechanisms in Gst gene repression.
Authors: Michael T McCabe; Jonathan A Low; Stephanie Daignault; Michael J Imperiale; Kirk J Wojno; Mark L Day Journal: Cancer Res Date: 2006-01-01 Impact factor: 12.701
Authors: X Lin; M Tascilar; W H Lee; W J Vles; B H Lee; R Veeraswamy; K Asgari; D Freije; B van Rees; W R Gage; G S Bova; W B Isaacs; J D Brooks; T L DeWeese; A M De Marzo; W G Nelson Journal: Am J Pathol Date: 2001-11 Impact factor: 4.307
Authors: Marta Camoriano; Shannon R Morey Kinney; Michael T Moser; Barbara A Foster; James L Mohler; Donald L Trump; Adam R Karpf; Dominic J Smiraglia Journal: Cancer Res Date: 2008-06-01 Impact factor: 12.701
Authors: Tin Oo Khor; Francisco Fuentes; Limin Shu; Ximena Paredes-Gonzalez; Anne Yuqing Yang; Yue Liu; Dominic J Smiraglia; Srinivasan Yegnasubramanian; William G Nelson; Ah-Ng Tony Kong Journal: Cancer Prev Res (Phila) Date: 2014-09-29
Authors: Chang Jun Liu; Jin Hui Yang; Fei Zhou Huang; Wan Pin Nie; Chu Ping Liu; Xian Hai Mao; Xin Min Yin; Xian Bo Shen; Chuang Peng; Mei Fu Chen; Bo Jiang; Xun Yang Liu; Jin Shu Wu Journal: Am J Transl Res Date: 2017-02-15 Impact factor: 4.060
Authors: Shannon R Morey Kinney; Michael T Moser; Marien Pascual; John M Greally; Barbara A Foster; Adam R Karpf Journal: Mol Cell Biol Date: 2010-06-28 Impact factor: 4.272